Peter Beitsch1, Pat Whitworth2, Paul Baron2, Michael C Rotkis3, Angela M Mislowsky4, Paul D Richards5, Mary K Murray6, James V Pellicane7, Carrie L Dul8, Charles H Nash9, Lisette Stork-Sloots10, Femke de Snoo10, Sarah Untch11, Laura A Lee12. 1. Targeted Medical Education, Dallas Breast Center, 8140 Walnut Hill Lane, Suite 800, Dallas, TX, 75231, USA. Beitsch@aol.com. 2. Targeted Medical Education, Nashville Breast Center, Nashville, TN, USA. 3. Breast & Melanoma Specialists of Charleston, Charleston, SC, USA. 4. Northern Indiana Cancer Research Consortium, South Bend, IN, USA. 5. Coastal Carolina Breast Center, Murrells Inlet, SC, USA. 6. Blue Ridge Cancer Care, Roanoke, VA, USA. 7. Cleveland Clinic Akron General, Akron, OH, USA. 8. Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA, USA. 9. St. John Region, Grosse Pointe Woods, MI, USA. 10. Northeast Georgia Medical Center, Gainesville, GA, USA. 11. Agendia Inc., Irvine, CA, USA. 12. Comprehensive Cancer Center, Palm Springs, CA, USA.
Abstract
BACKGROUND: Pertuzumab became a standard part of neoadjuvant therapy for human epidermal growth factor receptor 2-positive (HER2+) breast cancers approximately halfway through Neoadjuvant Breast Registry Symphony Trial (NBRST) enrollment, providing a unique opportunity to determine biologically which clinical HER2+ patients benefit most from dual targeting. As a neoadjuvant phase 4 study, NBRST classifies patients by both conventional and molecular subtyping. METHODS: Of 308 clinical HER2+ patients enrolled in NBRST between 2011 and 2014 from 62 U.S. institutions, 297 received neoadjuvant chemotherapy (NCT) with HER2-targeted therapy and underwent surgery. This study compared the pathologic complete response (pCR) rate of BluePrint versus clinical subtypes with treatment, specifically differences between trastuzumab (T) treatment and trastuzumab and pertuzumab (T/P) treatment. RESULTS: In this study, 60% of the patients received NCT-T, and 40% received NCT-T/P. The overall pCR rate (ypT0/isN0) was 47%. BluePrint classified 161 tumors (54%) as HER2 type, with a pCR rate of 65%. This was significantly higher than the pCR rate for the 91 HER2+ tumors (31%) classified as luminal (18%) (p = 0.00001) and the 45 tumors (15%) classified as basal (44%) (p = 0.0166). The patients treated with T/P had higher pCR rates than those treated with trastuzumab alone. The difference was most pronounced in the BluePrint luminal patients (8 vs. 31%). The highest pCR was reached by the BluePrint HER2-type patients treated with T/P (76%). CONCLUSIONS: The addition of pertuzumab leads to increased pCR rates for all HER2+ patient groups except for the BluePrint basal-type patients. This better response was most pronounced for the BluePrint luminal-type patients.
BACKGROUND:Pertuzumab became a standard part of neoadjuvant therapy for humanepidermal growth factor receptor 2-positive (HER2+) breast cancers approximately halfway through Neoadjuvant Breast Registry Symphony Trial (NBRST) enrollment, providing a unique opportunity to determine biologically which clinical HER2+ patients benefit most from dual targeting. As a neoadjuvant phase 4 study, NBRST classifies patients by both conventional and molecular subtyping. METHODS: Of 308 clinical HER2+ patients enrolled in NBRST between 2011 and 2014 from 62 U.S. institutions, 297 received neoadjuvant chemotherapy (NCT) with HER2-targeted therapy and underwent surgery. This study compared the pathologic complete response (pCR) rate of BluePrint versus clinical subtypes with treatment, specifically differences between trastuzumab (T) treatment and trastuzumab and pertuzumab (T/P) treatment. RESULTS: In this study, 60% of the patients received NCT-T, and 40% received NCT-T/P. The overall pCR rate (ypT0/isN0) was 47%. BluePrint classified 161 tumors (54%) as HER2 type, with a pCR rate of 65%. This was significantly higher than the pCR rate for the 91 HER2+ tumors (31%) classified as luminal (18%) (p = 0.00001) and the 45 tumors (15%) classified as basal (44%) (p = 0.0166). The patients treated with T/P had higher pCR rates than those treated with trastuzumab alone. The difference was most pronounced in the BluePrint luminal patients (8 vs. 31%). The highest pCR was reached by the BluePrint HER2-type patients treated with T/P (76%). CONCLUSIONS: The addition of pertuzumab leads to increased pCR rates for all HER2+ patient groups except for the BluePrint basal-type patients. This better response was most pronounced for the BluePrint luminal-type patients.
Authors: Ramon Colomer; Cristina Saura; Pedro Sánchez-Rovira; Tomás Pascual; Isabel T Rubio; Octavio Burgués; Lourdes Marcos; César A Rodríguez; Miguel Martín; Ana Lluch Journal: Oncologist Date: 2019-02-01
Authors: Pat W Whitworth; Peter D Beitsch; Mary K Murray; Paul D Richards; Angela Mislowsky; Carrie L Dul; James V Pellicane; Paul L Baron; Rakhshanda Layeequr Rahman; Laura A Lee; Beth B Dupree; Pond R Kelemen; Andrew Y Ashikari; Raye J Budway; Cristina Lopez-Penalver; William Dooley; Shiyu Wang; Patricia Dauer; Andrea R Menicucci; Erin B Yoder; Christine Finn; Lisa E Blumencranz; William Audeh Journal: JCO Precis Oncol Date: 2022-09
Authors: Josien C Haan; Rajith Bhaskaran; Architha Ellappalayam; Yannick Bijl; Christian J Griffioen; Ersan Lujinovic; William M Audeh; Frédérique Penault-Llorca; Lorenza Mittempergher; Annuska M Glas Journal: Genes Chromosomes Cancer Date: 2021-12-11 Impact factor: 4.263
Authors: Julia E C van Steenhoven; Anne Kuijer; Paul J van Diest; Joost M van Gorp; Marieke Straver; Sjoerd G Elias; Jelle Wesseling; Emiel Rutgers; Johanna N H Timmer-Bonte; Peter Nieboer; Tineke J Smilde; Alex Imholz; Charlotte F J M Blanken; Sabine Siesling; Thijs van Dalen Journal: Genes (Basel) Date: 2018-05-17 Impact factor: 4.096
Authors: Tamara Díaz-Redondo; Rocio Lavado-Valenzuela; Begoña Jimenez; Tomas Pascual; Fernando Gálvez; Alejandro Falcón; Maria Del Carmen Alamo; Cristina Morales; Marta Amerigo; Javier Pascual; Alfonso Sanchez-Muñoz; Macarena González-Guerrero; Luis Vicioso; Aurora Laborda; Maria Victoria Ortega; Lidia Perez; Aranzazu Fernandez-Martinez; Nuria Chic; Jose Manuel Jerez; Martina Alvarez; Aleix Prat; Nuria Ribelles; Emilio Alba Journal: Front Oncol Date: 2019-11-05 Impact factor: 6.244
Authors: Katalin Boér; Zsuzsanna Kahán; László Landherr; Tibor Csőszi; Károly Máhr; Ágnes Ruzsa; Zsolt Horváth; Barna Budai; Gábor Rubovszky Journal: Pathol Oncol Res Date: 2021-05-04 Impact factor: 3.201